<DOC>
	<DOCNO>NCT00645814</DOCNO>
	<brief_summary>Study Safety Efficacy Adalimumab Subjects Moderate Severe Chronic Plaque Psoriasis</brief_summary>
	<brief_title>Multicenter Study Safety Efficacy Adalimumab Subjects With Moderate Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Diagnosis moderate severe chronic plaque psoriasis Active psoriasis , despite topical therapy Other active skin disease skin infection Prior exposure antiTNF therapy Subject active skin diseases Multiple concomitant therapy restriction and/or washout ( topicals , UV , systemic PS therapy ) Poorly control medical condition History neurologic symptom suggestive central nervous system ( CNS ) demyelinate disease . History cancer lymphoproliferative disease History active TB listeriosis , persistent chronic active infection Known immune deficiency immunocompromised Clinically significant abnormal laboratory test result Erythrodermic psoriasis generalize pustular psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>